Group 1 - The core viewpoint of the article highlights the financial performance of Aikang Medical (01789.HK) for the first half of 2025, showing growth in both revenue and net profit compared to the same period in 2024 [1] - The company achieved sales revenue of approximately RMB 694.2 million, representing an increase of about 5.6% year-on-year [1] - The net profit for the same period was approximately RMB 160.6 million, reflecting a year-on-year increase of about 15.3% [1] Group 2 - The growth in sales and profit is attributed to the implementation of volume-based procurement policies, which have accelerated the import substitution process [1] - There has been a continuous increase in the demand for the company's surgical products, contributing to further growth in sales of volume-based products [1]